Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002637 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00002637: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002637 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002637, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy using interleukin-2 and interferon gamma in treating patients with advanced prostate cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon gamma
- BIOLOGICAL gene-modified tumor cell vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1995-01 |
| Est. Completion | 2001-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002637
The ClinicalTrials.gov registry entry for NCT00002637 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00002637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002637 about?
NCT00002637 is a clinical study titled "Biological Therapy in Treating Patients With Prostate Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. ...
What is the current status of trial NCT00002637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1995-01. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00002637?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL), gene-modified tumor cell vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002637?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.